drugset
drugset / Trial / NCT06034275

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

NCT06034275 ↗

Phase 1 Recruiting 36 enrolled Vincerx Pharma, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

Timeline

Start
2023-09-13
Primary completion
2025-05-30
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject VIP943 Unknown — Intravenous

Indications

B-cell acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome